2. Signaling Pathways
  3. Metabolic Enzyme/Protease
    Neuronal Signaling
  4. FAAH

FAAH

Fatty acid amide hydrolase

FAAH

Related Products

PDF 0.4 MB

FAAH (Fatty acid amide hydrolase) is a membrane-bound protein belonging to serine hydrolase family of enzymes.FAAH is responsible for the hydrolysis of a number of important endogenous fatty acid amides, including the endogenous cannabimimetic agent anandamide (AEA), the sleep-inducing compound oleamide, and the putative anti-inflammatory agent palmitoylethanolamide (PEA). FAAH plays a significant role in termination of signalling of a class of bioactive lipids called fatty acid amides (FAAs) both in the central nervous system (CNS) and peripheral tissues.

FAAH belongs to the amidase signature (AS) superfamily and is widely distributed in multicellular eukaryotes. FAAH has a key role in the control of the cannabinoid signaling, through the hydrolysis of the endocannabinoids anandamide and in some tissues 2-arachidonoylglycerol.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-14595
    Biochanin A
    		Inhibitor 99.01%
    Biochanin A is a naturally occurring fatty acid amide hydrolase (FAAH) inhibitor, which inhibits FAAH with IC50s of 1.8, 1.4 and 2.4 μM for mouse, rat, and human FAAH, respectively.
    Biochanin A
  • HY-B1227
    Carprofen
    		Inhibitor 99.76%
    Carprofen is a nonsteroid anti-inflammatory agent, acts as a multi-target FAAH/COX inhibitor, with IC50s of 3.9 μM, 22.3 μM and 78.6 μM for COX-2, COX-1 and FAAH, respectively.
    Carprofen
  • HY-B0182
    Carmofur
    		Inhibitor 99.95%
    Carmofur (HCFU) is a rat recombinant acid ceramidase inhibitor with an IC50 of 29 nM. Carmofur is also a protease inhibitor of SARS-CoV-2 main protease (Mpro), fatty acid amide hydrolase (FAAH) and N-acylethanolamine acid amidase (NAAA). Carmofur has anti-cancer, anti-inflammatory and anti-virus activities, and can be used for the study of COVID-19 and acute lung injury (ALI).
    Carmofur
  • HY-119283
    MAGL-IN-5
    		Inhibitor 99.73%
    MAGL-IN-5 (CAY10499) is a non-selective lipase inhibitor with IC50 values of 144, 90, and 14 nM for human recombinant monoacylglycerol lipase(MAGL),hormone sensitive lipase(HSL), and fatty acid amide hydrolase(FAAH) respectively.
    MAGL-IN-5
  • HY-10864
    URB-597
    		Inhibitor 98.96%
    URB-597 (KDS-4103) is an orally bioavailable and selective FAAH inhibitor. URB-597 inhibits FAAH activity with an IC50s of approximately 5 nM in rat brain membranes, 0.5 nM in intact rat neurons, 3 nM in human liver microsomes. Antidepressant-like effects. Analgesic activity.
    URB-597
  • HY-164495
    Sob-AM2
    Sob-AM2 is a potent substrate targeting fatty acid amide hydrolase (FAAH) expressed in the brain (Km=1.3 μM), delivering high concentrations of Sobetirome (HY-14823) to the central nervous system with minimal peripheral systemic dose, thereby stimulating central thyroid hormone receptor β (TRβ).
    Sob-AM2
  • HY-B1227R
    Carprofen (Standard)
    		Inhibitor
    Carprofen (Standard) is the analytical standard of Carprofen. This product is intended for research and analytical applications. Carprofen is a nonsteroid anti-inflammatory agent, acts as a multi-target FAAH/COX inhibitor, with IC50s of 3.9 μM, 22.3 μM and 78.6 μM for COX-2, COX-1 and FAAH, respectively.
    Carprofen (Standard)
  • HY-103338
    AM1172
    		Inhibitor
    AM1172 is metabolically stable anandamide uptake inhibitor and FAAH inhibitor.
    AM1172
  • HY-14380
    PF-3845
    		Inhibitor 99.95%
    PF-3845 is a potent, selective, irreversible and orally active inhibitor of fatty acid amide hydrolase (FAAH), with a Ki of 0.23 μM. PF-3845 is a covalent inhibitor that carbamylates FAAH's serine nucleophile. PF-3845 can reduce pain sensation, inflammation, and anxiety/depression without substantial effects on motility or cognition.
    PF-3845
  • HY-14376
    Redafamdastat
    		Inhibitor 99.89%
    Redafamdastat (PF-04457845) is a highly efficacious and selective FAAH inhibitor with IC50 values is 7.2±0.63 nM and 7.4±0.62 nM for hFAAH and rFAAH, respectively.
    Redafamdastat
  • HY-15250
    JZL195
    		Inhibitor 99.75%
    JZL195 is a selective and efficacious dual fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) inhibitor with IC50s of 2 and 4 nM, respectively.
    JZL195
  • HY-19740
    BIA 10-2474
    		Inhibitor 99.39%
    BIA 10-2474 is an inhibitor of fatty acid amide hydrolase (FAAH) with IC50 values of 50 to 70mg/kg in various rat brain regions.
    BIA 10-2474
  • HY-N7062
    JNJ-1661010
    		Inhibitor 99.77%
    JNJ-1661010 (Takeda-25) a potent and selective fatty acid amide hydrolase (FAAH) inhibitor with IC50s of 34 and 33 nM for rat FAAH and human FAAH, respectively. JNJ-1661010 can cross the blood-brain barrier and used as broad-spectrum analgesics.
    JNJ-1661010
  • HY-N2512
    1-Monomyristin
    		Inhibitor ≥98.0%
    1-Monomyristin, extracted from Serenoa repens, inhibits the hydrolysis of 2-oleoylglycerol (IC50=32 μM) and fatty acid amide hydrolase (FAAH) activity (IC50=18 μM). 1-Monomyristin shows antibacterial activity against Staphylococcus aureus and Aggregatibacter actinomycetemcomitans and also antifungal activity against Candida albicans.
    1-Monomyristin
  • HY-136924
    FP-Biotin
    		99.84%
    FP-biotin is a potent organophosphorus toxicant, well-suited for searching for new biomarkers of organophosphorus toxicants exposure. FP-Biotin quantifies FAAH, ABHD6, and MAG-lipase activity. FP-biotin is used for studies with plasma because biotinylated peptides are readily purified by binding to immobilized avidin beads.
    FP-Biotin
  • HY-116477
    URB937
    		Inhibitor 99.85%
    URB937 is an orally active and peripherally restricted FAAH inhibitor (IC50=26.8 nM) and increases anandamide levels. URB937 fails to affect FAAH activity in the brain (not penetrate the blood-brain barrier).
    URB937
  • HY-10865
    LY2183240
    		Inhibitor 98.01%
    LY2183240 is a highly potent blocker of anandamide uptake (IC50= 270 pM; Ki=540 nM). LY2183240 is a potent, covalent inhibitor of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) with an IC50 of 12.4 nM. LY2183240 inactivates FAAH by carbamylation of the enzyme's serine nucleophile. LY2183240 also inhibits several other brain serine hydrolases with IC50s of 5.3, 0.09, 8.2 nM for MAG lipase, bh6 and KIAA1363, respectively .
    LY2183240
  • HY-125967
    AM 374
    		Inhibitor
    AM 374 is an fatty acid amide hydrolase (FAAH) inhibitor. AM 374 inhibits amidase activity with an IC50 value of 13 nM. AM 374 can be used for the research of neurological disease.
    AM 374
  • HY-79511
    FAAH-IN-2
    		Inhibitor 98.21%
    FAAH-IN-2 (O-Desmorpholinopropyl Gefitinib) is a potent FAAH(fatty acid amide hydrolase) inhibitor extracted from Patent WO/2008/100977A2.
    FAAH-IN-2
  • HY-19636
    JNJ-42165279
    		Inhibitor 99.87%
    JNJ-42165279 is an orally active FAAH inhibitor, with IC50 values of 70 nM for hFAAH and 313 nM for rFAAH. JNJ-42165279 can be used in research related to the field of neuropathic pain.
    JNJ-42165279
Cat. No. Product Name / Synonyms Application Reactivity